Patent: 7,196,054

Summary for Patent: 7,196,054

Title:	Methods for treating wound tissue and forming a supplemented fibrin matrix
Abstract:	This invention provides supplemented and unsupplemented tissue sealants as well as methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one antimicrobial composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.
Inventor(s):	Drohan; William N. (Springfield, VA), MacPhee; Martin J. (Darnestown, MD), Nunez; Hernan (Derwood, MD), Liau; Gene (Wayland, MA), Maciag; Thomas (Portland, ME), Burgess; Wilson H. (Clifton, VA)
Assignee:	The American National Red Cross (Rockville, MD)
Application Number:	08/485,883
Patent Claims:	see list of patent claims

United States Patent 7,196,054 (Fibrinogen Dry-Powder Fibrin Matrix) Claims & US Patent Landscape Analysis

US Patent 7,196,054 covers dry-powder fibrin sealant/matrix methods for wound treatment using fibrinogen + thrombin + Factor XIII + Ca++, with collagen-free and no added fibrinolysis inhibitor, and with optional supplements (including growth factors, antimicrobials, analgesics, cytotoxins, and sustained-release agents), plus optional propellant and recombinant proteins.

This patent’s enforceable value depends on how narrowly its independent claims map to commercial products that (1) use dry powder with site-mixed aqueous solution, (2) include Factor XIII in the clot-formation system, and (3) avoid both collagen and added antifibrinolytics.

---

What claims does US Patent 7,196,054 include for dry powder fibrin matrices?

Core claim architecture (independent claims 1, 19, 37, 38):

1. Method of treating wounded tissue by applying a dry powder composition containing fibrinogen that forms a fibrin matrix when mixed in situ with:
   • thrombin
   • Factor XIII
   • Ca++
   • aqueous solution provided at the site
2. Composition limitations:
   • free of collagen
   • contains no added fibrinolysis inhibitor
3. Functional limitation:
   • fibrin matrix covering and adhering to wounded tissue
4. Supplemental embodiments:
   • adding an additional “supplement” to achieve therapeutic goals, including localized sustained release exceeding simple diffusion.
5. Secondary formulation features:
   • optional recombinantly produced human fibrinogen/thrombin/Factor XIII
   • optional propellant and specific propellant examples
   • optional diluent/filler/excipient (e.g., sucrose)
   • optional antioxidant
   • optional heparin as a “regulatory compound” affecting growth factor biology
   • optional inclusion of various classes of co-therapeutics (antimicrobials, growth factors, cytotoxins, etc.)

Claim set compression: what is actually “the invention”?

Most of the dependent claims expand scope by adding:

• which supplemental agents can be loaded
• whether the proteins are recombinant
• device-level packaging features (propellant)
• excipients and stabilization (sucrose, antioxidants)
• mechanistic/regulatory features (heparin with growth factors)
• sustained-release characteristics (release kinetics and solubility relationships)

From an infringement standpoint, the tightest bottleneck is usually the combination of:

• dry powder format
• in situ aqueous activation
• Factor XIII present in the clotting system
• no collagen
• no added fibrinolysis inhibitor

If a product uses fibrin sealant kits with thrombin + fibrinogen but without Factor XIII or without a dry powder format (for example, premixed two-syringe liquid systems), the independent claims narrow quickly.

---

Which parts of the patent claims are composition-matrix-limited vs. supplement-limited?

Matrix formation is the claim spine

Across independent claims, the “structural” requirements are consistent:

• dry powder containing fibrinogen
• aqueous solution delivered at wound site
• thrombin + Factor XIII + Ca++ provided so a fibrin matrix forms in situ
• collagen excluded
• added fibrinolysis inhibitor excluded

This makes the patent more about the clot-forming system configuration than about any single supplement.

Supplements are broad but still constrained

The supplement claims are very broad by category (growth factors, antibiotics, analgesics, antibodies, cytotoxins). However:

• the supplement must be incorporated in the composition and then
• (for key embodiments) must have sustained-release properties tied to dissolution of the fibrin clot and kinetic comparisons to diffusion.

That kinetic language (“sustained period greater than simple diffusion kinetics” and “amount greater than soluble in the fibrin matrix”) can be a litigation lever: it forces defendants to address whether their release profile meets the claimed performance relationships.

---

What is the patent’s key differentiation: Factor XIII plus collagen-free, no added fibrinolysis inhibitor?

US 7,196,054 is notable because it does not just claim fibrinogen + thrombin clotting. It requires:

• Factor XIII as part of the thrombin-mediated fibrin formation environment.
• no collagen (collagen-free)
• no added fibrinolysis inhibitor (so clot breakdown is not pharmacologically blocked using an added antifibrinolytic)

In practical terms:

• Many fibrin sealant products or hemostatic compositions historically used antifibrinolytic components (commonly aprotinin or tranexamic acid) to improve durability.
• Many tissue sealant approaches also use collagen matrices or collagen carriers.

So the claim’s value is driven by separating the “fibrin matrix” system from those common add-ons:

• no collagen carrier
• no antifibrinolytic added

If a competitor uses an antifibrinolytic in the final kit, the independent claims 1/19/37/38 are directly implicated for avoidance-by-design.

---

How do the supplemental sustained-release claims work legally and technically (claims 15–17 and 38)?

Claim 15–17: release duration and interaction

• Sustained period must be greater than simple diffusion kinetics.
• Supplement interacts with the fibrin matrix to increase longevity/stability of the matrix versus unsupplemented fibrin.
• Low solubility can be used to enable localized sustained-release and longer-than-diffusion kinetics.

Claim 38: additional quantitative relationships

Claim 38 adds multiple performance relationships:

• supplement is releasable upon dissolution of the clot for a sustained period
• amount of supplement in composition is greater than the amount soluble in the fibrin matrix
• sustained period greater than simple diffusion kinetics

Litigation effect

These provisions can be enforced through:

• product characterization and release testing
• evidence of whether the supplement’s solubility in the fibrin matrix is exceeded
• comparative release modeling vs diffusion controls

For defendants, these are common “expert-testable” claims that can support an invalidity argument if the release kinetics and solubility relationships were already known for fibrin matrices and diffusion-limited release systems.

---

What formulations are covered: dry powder with site-provided aqueous solution, propellant, and excipients?

Dry powder plus site-mixed activation

A defining element is that the aqueous solution is provided at the wound site and forms the fibrin matrix when combined with the dry powder fibrinogen and the thrombin/Factor XIII/Ca++ components.

This maps to a specific manufacturing and delivery paradigm:

• storage stability as a dry component
• on-site reconstitution/activation using a separate aqueous source

Propellant (claims 26–27, plus boiling point language in 34)

The patent includes an embodiment with a physiologically acceptable propellant, including:

• carbon dioxide
• nitrogen
• chlorofluorocarbons
• hydrofluorocarbons and adds the specific constraint that the boiling point is below physiological temperature.

That can matter for infringement because many products deliver sealant via dual-syringe liquid deposition rather than aerosolized/delivered dry systems.

Excipients, diluents, fillers (claims 31–35)

• at least one pharmaceutically acceptable diluent/filler/excipient
• increases solubility of the fibrin sealant composition
• sucrose is explicitly called out

Antioxidant (claim 33)

The patent includes antioxidants, but does not limit to a specific class, leaving a wide net for formulation variants.

---

Which subject matter is explicitly optional but still could anchor infringement (recombinant proteins, heparin, growth factors)?

Recombinant fibrinogen, thrombin, Factor XIII (claims 22–24)

These dependent claims suggest an anticipated product version using recombinant proteins. In enforcement, they broaden the claim set for defendants who adopt recombinant biologics.

Growth factors (claims 7–9, 25)

The patent enumerates categories and specific examples, including:

• FGF-1, FGF-2, FGF-4
• PDGF
• IGF-1, IGF-2
• EGF
• TGF-β
• cartilage/osteogenic inducing factors
• heparin-binding growth factors
• cytokines/interferons/VEGF in the broader list

Heparin as “regulatory compound” (claims 28–30, 36)

Heparin is used as a regulatory compound to:

• potentiate growth factor activity and/or
• inhibit agents interfering with growth factor mediated processes

For infringement, the presence of heparin in a defined mechanistic functional role becomes relevant only if the accused product meets the claim logic around growth factor regulation.

---

What patent estate exists around dry-powder fibrin sealants, Factor XIII, and collagen-free systems? (How to position 7,196,054 among competitors)

Because US 7,196,054 is a single patent number with a claim set you provided, a full “landscape” requires knowing:

• the assignee(s)
• the priority dates
• the application family
• forward citations and related continuations
• competitor products and their compositions

That information is not present in the prompt. Under the constraints, no landscape can be accurately constructed without specific patent numbers, assignees, and jurisdictions.

Accordingly, the analysis below restricts to claim-driven competitive positioning rather than naming other patents or asserting citation counts.

Claim-driven “where this sits” in the ecosystem

US 7,196,054 sits at the intersection of four technical themes that are often separately patented:

1. Fibrin sealant generation method (fibrinogen + thrombin)
2. Factor XIII incorporation to strengthen/affect the fibrin matrix
3. Dry powder + site activation for delivery and stability
4. Supplement loading and sustained release from the fibrin matrix
5. Avoidance choices: no collagen, no added fibrinolysis inhibitor

Competitors that use:

• collagen carriers, or
• antifibrinolytics added to stabilize clot persistence, or
• liquid premix systems not requiring dry powder activation will have a structural route to design-around the independent claims.

Competitors that:

• use dry powder fibrinogen with in situ aqueous activation
• include Factor XIII in the clot-forming mix
• exclude collagen and avoid added antifibrinolytic face the tightest alignment risk.

---

When does the patent lose exclusivity in the US?

A time-to-expiry analysis requires the patent’s filing date, issuance date, and any adjustments (and whether it is subject to term adjustments/extensions under US law). None of those dates are provided.

No accurate exclusivity timeline can be produced.

---

What are the likely generic/biologic entry risks: Paragraph IV vs biosimilar vs formulation carve-outs?

A typical risk map depends on whether the patented matter is tied to:

• a new active ingredient (unlikely here; fibrinogen/thrombin are known),
• a device/kit delivery system, or
• a method of treatment used with a particular product.

US 7,196,054 is method-focused. For entry risk scenarios:

• A generic firm would generally need an FDA regulatory pathway that permits marketing without the infringing method use, or it would need a design-around that changes claim elements (dry powder format, Factor XIII presence, collagen-free, no added antifibrinolytic, or release kinetics).
• If a competitor makes a different formulation or changes the clotting components, infringement may be avoided even if fibrin sealant use remains similar.

A full risk quantification requires the product label, kit composition, and FDA status, which are not provided.

---

How strong are the claims (critical legal posture for enforcement): key vulnerability points

Even without the prior-art/patent family record, the claim language suggests typical strengths and attack surfaces.

Strengths

• Clear structural constraints (dry powder, in situ aqueous solution, Factor XIII + Ca++ + thrombin, collagen-free, no added fibrinolysis inhibitor).
• Supplement categories are broad enough to capture a range of marketed fibrin therapies.
• Sustained-release performance relationships provide measurable endpoints.

Attack surfaces

• “No added fibrinolysis inhibitor” can be fact-dependent. If a formulation includes antifibrinolytics as impurities, residues, or components not characterized as inhibitors, claim mapping can become contentious.
• “Free of collagen” is also composition- and assay-dependent.
• Sustained release vs “simple diffusion kinetics” can be challenged as indefinite/unclear or as not supported by a specific measurement method.
• Growth factor biology/regulatory compound “heparin potentiating and inhibiting interfering agents” may be litigated through functional definition issues and whether the accused product achieves the same mechanism, not merely includes heparin.

---

Key Takeaways

• US 7,196,054 targets dry-powder fibrinogen systems that form an in situ fibrin matrix using thrombin + Factor XIII + Ca++, with collagen-free and no added fibrinolysis inhibitor limitations.
• The broad commercial relevance comes from supplement loading and sustained-release embodiments tied to diffusion kinetics comparisons and solubility relationships.
• The most defensible infringement hook for a claimant is likely the combination of: dry powder format + Factor XIII + collagen-free + no added antifibrinolysis + in situ aqueous activation.
• The most straightforward design-around paths for competitors are likely structural: omit Factor XIII or introduce collagen or antifibrinolytic components, or switch to a delivery format that does not meet the “dry powder + site aqueous solution” requirement.

---

FAQs

1. What claim elements in US 7,196,054 most strongly differentiate it from conventional two-syringe fibrin sealants?
2. How does “no added fibrinolysis inhibitor” affect infringement risk if a product includes antifibrinolytic agents for clot durability?
3. Do the growth factor and heparin “regulatory compound” claims require specific mechanistic evidence or only composition-level proof?
4. What tests would typically be used to prove sustained-release is “greater than simple diffusion kinetics” for a supplement in fibrin matrices?
5. If a competitor uses recombinant proteins vs plasma-derived proteins, which dependent claims of US 7,196,054 become directly relevant?

---

References (APA)

1. United States Patent 7,196,054, claims as provided in the prompt.

Details for Patent 7,196,054

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978		2015-06-07
Ethicon, Inc.	EVARREST	fibrin sealant patch	Patch	125392	December 05, 2012		2015-06-07
Ethicon, Inc.	EVARREST	fibrin sealant patch	Patch	125392	May 16, 2013		2015-06-07
Ethicon, Inc.	EVARREST	fibrin sealant patch	Patch	125392	May 27, 2014		2015-06-07